

PATENT  
Docket No. 529492000100

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of:

Mark A. SCHENA

Serial No.: 09/613,006

Filing Date: July 10, 2000

For: MICROARRAY METHOD OF  
GENOTYPING MULTIPLE SAMPLES  
AT MULTIPLE LOCI

Examiner: B. Forman

Group Art Unit: 1634

DECLARATION OF MARK A. SCHENA  
PURSUANT TO 37 C.F.R. § 1.131

Commissioner for Patents  
Alexandria, VA 22313-1450

Dear Sir:

I, Mark A. Schena, declare as follows:

1. I am the sole inventor named in the above-referenced patent application, and I am familiar with the contents thereof.
2. The work was completed by me or under my direction.
3. I conceived of the invention claimed in the subject application prior to February 16, 2000.
4. I have worked diligently on reducing to practice the claimed invention in the subject application since before February 16, 2000 until the application was filed on July 10, 2000.

pa-786483

5. The following paragraph summarizes the document attached to this declaration which is submitted as evidence that I conceived of the claimed invention in the subject application prior to February 16, 2000. The attached document was prepared in the U.S. All of the activities reported in the document occurred in the U.S. With respect to this document, dates and portions that are not relevant to this declaration have been redacted.

6. Exhibit A is evidence of my conception of the claimed invention in the subject application. The conception was made on a date prior to February 16, 2000.

7. The following paragraph summarizes the documents attached to this declaration which are submitted as evidence that I was diligent in reducing the claimed invention in the subject application to practice. All of the attached documents were prepared in the U.S. prior to the filing date of July 10, 2000. All of the activities reported in these documents occurred in the U.S. in a diligent manner during a period commencing prior to February 16, 2000 and ending prior to July 10, 2000. With respect to all of these documents, dates (all of which are prior to July 10, 2000) and portions that are not relevant to this declaration have been redacted.


8. Exhibit B shows computer files and pages from my laboratory notebooks that show that I worked diligently on the reduction of the claimed invention to practice. Pages 1 – 6 show computer files of data generated from experiments. Page 7 shows the sequences of oligonucleotides used in experiments. Page 8 shows a protocol used in the experiments. Page 9 shows the sequences of oligonucleotides used in the experiments. Pages 10 – 11 show a sequence alignment generated in the experiments. Pages 12 – 14 show the sequences of oligonucleotides used in the experiments. Pages 15 – 18 show nucleotide sequences analyzed in the experiments. Pages 19 – 21 show protocols used in experiments. Page 22 shows numerical microarray data. Pages 23 – 30 show pictorial microarray data.

I hereby declare that all statements made herein of my knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application, any patent issuing thereon, or any patent to which this verified statement is directed.

5/3/03  
Date

Mark A. Schena  
Mark A. Schena


NOTES




∴ Multiple patients + multiple  
diseases in one test ⇒ Cost-effective!

- Vizit board
- Aharan re: Stranberg MS?


# Exhibit B




# Exhibit B



# Exhibit B



# Exhibit B





# Exhibit B





Exhibit B



**Exhibit B**

ARDC-110 (Green Label, Sickle Cell WT)  
5' NGA CTC CTG (A/T)GG AGA A 3'  
N = Cy3

A1 → E1  
+  
A3 → E3

ARDC-111 (Red Label, Sickle Cell C allele)  
5' NGA CTC CTA (A/T)GG AGA A 3'  
N = Cy5

ARDC-112 (Red Label, Sickle Cell WT)  
5' NTG GTG GTG AGG CCC T 3'  
N = Cy5

ARDC-113 (Green Label, Sickle Cell S allele)  
5' NTG GTG GTA AGG CCC T 3'  
N = Cy3

ARDC-114 (Green Label, CF WT)  
5' NAT CAT CTT TGG TGT T 3'  
N = Cy3

ARDC-115 (Red Label, CF ΔF508)  
5' NTA TCA TCG GTG TTT C 3'  
N = Cy5

ARDC-116 (Red Label, GALT Q188R WT)  
5' NCA CTG CCA GGT AAG G 3'  
N = Cy5

ARDC-117 (Green Label, GALT Q188R mutant)  
5' NCA CTG CCG GGT AAG G 3'  
N = Cy3

ARDC-118 (Green Label, N314D WT)  
5' NCA ACT GGA ACC ATT G 3'  
N = Cy3

ARDC-119 (Red Label, N314D mutant)  
5' NCA ACT GGG ACC ATT G 3'  
N = Cy5

b. Plasmid DNA can be prepared by alkaline lysis and purified. The 96-well REAL prep (Qiagen #SQ811 and #19504) facilitates rapid preparation.

[Back to Table of Contents](#)

#### Protocol 4. Microarray manufacture and processing.

##### Reagents and Equipment

- Micro-spotting robot (Various)
- Stealth Micro Spotting Device (TeleChem)
- SuperAldehyde Substrates (TeleChem)

##### Method

1. Obtain cilylated (active aldehyde) microscope slides (CEL Associates).
2. Print amino-linked cDNAs using a micro-spotting device according to the manufacturer's instructions.
3. Allow printed microarrays to dry overnight in a slide box<sup>a</sup>.
4. Soak slides twice in 0.2% SDS for 2 min at room temperature with vigorous agitation<sup>b</sup>.
5. Soak slides twice in ddH<sub>2</sub>O for 2 min at room temperature with vigorous agitation.
6. Transfer slides into ddH<sub>2</sub>O at 95-100°C for 2 min to allow DNA denaturation.
7. Allow slides to dry thoroughly at room temperature (~5 min).
8. Transfer slides into a sodium borohydride solution<sup>c</sup> for 5 min at room temperature to reduce free aldehydes.
9. Rinse slides three times in 0.2% SDS for 1 min each at room temperature.
10. Rinse slides once in ddH<sub>2</sub>O for 1 min at room temperature.
11. Submerge slides in ddH<sub>2</sub>O at 95-100°C for 2 seconds<sup>d</sup>.
12. Allow the slides to air dry and store in the dark at 25°C (stable for >1 year).
  - a. Drying increases crosslinking efficiency. Several days or more is acceptable.
  - b. This step removes salt and unbound DNA.
  - c. Dissolve 1.0 g NaBH<sub>4</sub> in 300 ml phosphate buffered saline (PBS). Add 100 ml 100% ethanol to reduce bubbling. Prepare JUST PRIOR to use!
  - d. Heating the slides greatly aids in the drying process.

##### Method

1. Prepare a 15-mer<sup>a</sup> oligonucleotide microarray wherein the central (8<sup>th</sup>) position identifies the polymorphism or mutation in the fluorescent sample<sup>b</sup>. Microarrays are made by spotting 10-100 pmole/μl oligonucleotides in 1X micro-spotting solution.
2. Process the microarray to remove unbound 15-mer.
3. Prepare a fluorescent sample by PCR amplification of the locus encompassing the polymorphism or mutation<sup>c</sup>. Use ~1/10 of a 100 μl PCR reaction for hybridization of a sample that contains <1,000 loci. Purify the sample prior to hybridization by ethanol precipitation or spin column purification.
4. Denature the sample by boiling for 2 min prior to hybridization<sup>d</sup>.
5. Hybridize the fluorescent sample to the oligonucleotide microarray for 4 hrs at 42°C<sup>e</sup>.
6. Wash the microarray to remove unhybridized sample as follows: twice for 5 min each at room temperature in 2X SSC, once for 5 min at room temperature in 2X SSC.
7. Allow the microarray to air dry.
8. Scan the microarray at the highest PMT and laser settings that preserve linearity and minimize background<sup>f</sup>.
9. Quantify fluorescent intensities with Image software.
- a. Oligonucleotides must be coupled covalently to the solid support. We have used microscope slides with reactive aldehyde groups and primary amines on the oligonucleotides to mediate covalent end attachment.
- b. The central or 8<sup>th</sup> position in a 15-mer is used to identify a single base polymorphism or mutation by hybridization. For a marker in which the wild type is a "G" and the mutant is a "T", the two complementary 15-mers would be identical except at position 8 in which the wild type 15-mer would contain a "C" and the mutant oligonucleotide would contain an "A".
- c. Fluorescent primers spanning the site of interest by ~60 bp will yield a product that hybridizes efficiently to the oligonucleotide microarray.
- d. Double-stranded fluorescent products must be denatured prior to hybridization. Single-stranded fluorescent samples made by Mosaic PCR are preferable.
- e. Hybridization temperature should be ~10°C below the T<sub>m</sub>. 42°C works well for 15-mers. The temperature should be adjusted for longer or shorter oligonucleotides.
- f. On the ScanArray 3000, laser and PMT settings of 70% and 80%, respectively, work well for most genotyping applications.

[Back to Table of Contents](#)

#### Literature Cited

1. M. Schena and R.W. Davis (1998). Genes, Genomes and Chips. In DNA Microarrays: A Practical Approach (ed. M. Schena), Oxford University Press, Oxford, UK, in press.
2. Schena, M. and R.W. Davis (1998). Parallel Analysis with Biological Chips. In PCR Methods Manual (eds. M. Innis, D. Gelfand, J. Sninsky), Academic Press, San Diego, in press.
3. Lemieux, B., Abruzzo, A., and M. Schena (1998). Overview of DNA Chip Technology. Molecular Breeding 4, 277-280.
4. Schena, M., Heller, R.A., Thierhalt, T.P., Konrad, K., Lachmezier, E., and R.W. Davis (1998). Microarrays: biotechnology's discovery platform for functional genomics. Trends in Biotechnology 16, 301-306.
5. Heller, R.A., Schena, M., Chai, A., Shalon, D., Bedilion, T., Gilmore, J., Woolley, D.E., and Davis, R.W. (1997). Discovery and analysis of inflammatory disease-related genes using cDNA microarrays. Proceedings of the National Academy of Sciences USA 94, 2150-2155.
6. Schena, M., Shalon, D., Heller, R., Chai, A., Brown, P.O., and R.W. Davis. (1996). Parallel Human Genome Analysis: Microarray-Based Expression Monitoring of 1,000 Genes. Proceedings of the National Academy of Sciences USA 93, 10614-10619.
7. Schena, M. (1996). Genome analysis with gene expression microarrays. BioEssays 18, 427-431.
8. Schena, M., Shalon, D., Davis, R.W., and Brown, P.O. (1995). Quantitative monitoring of gene expression patterns with a complementary DNA microarray. Science 270, 467-470.

## Exhibit B

## EOS BIOTECHNOLOGY: OLIGO RECORD FILE

Run Title: ArrayIt  
 340 Plate 1  
 NOTES: "Cy3/Cy5/Aminolink 15mers, and Aminolink 20mers"

SERIAL NUMBER:		300003401							
#	NAME	5' SP	5' --> 3' SEQUENCE	Plate	Row	Plate Col.	Run	Comment	
	amount (ug)		amount (nmol)						
1	ARDC-110	CY3	GACTCCTGWGGAGAA	A	1	23.42	4.82	} Cy3 probe	
2	ARDC-113	CY3	TGGTGGTAAGGCCCT	B	1	32.92	6.77		
3	ARDC-114	CY3	ATCATCTTTGGTGTT	C	1	33.30	6.93		
4	ARDC-117	CY3	CACTGCCGGGTAAGC	D	1	29.24	6.02		
5	ARDC-118	CY3	CAACTGGAACCATTG	E	1	25.85	5.39		
6	ARDC-110	CY3	GACTCCTGWGGAGAA	F	1	24.54	5.05		
7	ARDC-113	CY3	TGGTGGTAAGGCCCT	G	1	29.27	6.02		
8	ARDC-114	CY3	ATCATCTTTGGTGTT	H	1	27.18	5.66		
9	ARDC-117	CY3	CACTGCCGGGTAAGG	A	2	26.59	5.48	} Cy5 probe	
10	ARDC-118	CY3	CAACTGGAACCATTG	B	2	25.93	5.40		
11	ARDC-110	CY3	GACTCCTGWGGAGAA	C	2	21.59	4.44		
12	ARDC-113	CY3	TGGTGGTAAGGCCCT	D	2	34.51	7.10		
13	ARDC-114	CY3	ATCATCTTTGGTGTT	E	2	36.17	7.53		
14	ARDC-117	CY3	CACTGCCGGGTAAGG	F	2	28.14	5.80		
15	ARDC-118	CY3	CAACTGGAACCATTG	G	2	27.07	5.64		
16			H 2						
17	ARDC-111	CY5	GACTCCTAWGGAGAA	A	3	26.60	5.49		
18	ARDC-112	CY5	TGGTGGTGAGGCCCT	B	3	32.80	6.72		
19	ARDC-115	CY5	TATCATCGGTGTTTC	C	3	20.76	4.34		
20	ARDC-116	CY5	CACTGCCAGGTAAGG	D	3	23.47	4.85		
21	ARDC-119	CY5	CAACTGGGACCATTG	E	3	22.62	4.70		
22	ARDC-111	CY5	GACTCCTAWGGAGAA	F	3	22.88	4.72		
23	ARDC-112	CY5	TGGTGGTGAGGCCCT	G	3	26.28	5.39		
24	ARDC-115	CY5	TATCATCGGTGTTTC	H	3	17.87	3.73		
25	ARDC-116	CY5	CACTGCCAGGTAAGG	A	4	22.40	4.63		
26	ARDC-119	CY5	CAACTGGGACCATTG	B	4	31.33	6.51		
27	ARDC-111	CY5	GACTCCTAWGGAGAA	C	4	24.06	4.97		
28	ARDC-112	CY5	TGGTGGTGAGGCCCT	D	4	36.45	7.47		
29	ARDC-115	CY5	TATCATCGGTGTTTC	E	4	23.95	5.00		
30	ARDC-116	CY5	CACTGCCAGGTAAGG	F	4	26.93	5.56		
31	ARDC-119	CY5	CAACTGGGACCATTG	G	4	31.42	6.52		
32			H 4						
33	ARDC-120	L	TTCTCCWCAGGAGTC	A	5	21.64	4.38	} Assume 5 wait us Control Oligos.	
34	ARDC-121	L	AGGGCCTCACCACCA	B	5	40.17	8.16		
35	ARDC-122	L	AACACCAAAGATGAT	C	5	30.43	6.09		
36	ARDC-123	L	CCTTACCTGGCAGTG	D	5	26.44	5.33		
37	ARDC-124	L	CAATGGTTCCAGTTG	E	5	28.09	5.62		
38	ARDC-120	L	TTCTCCWCAGGAGTC	F	5	20.54	4.16		
39	ARDC-121	L	AGGGCCTCACCACCA	G	5	21.05	4.28		
40	ARDC-122	L	AACACCAAAGATGAT	H	5	22.33	4.47		
41	ARDC-123	L	CCTTACCTGGCAGTG	A	6	27.25	5.49		
42	ARDC-124	L	CAATGGTTCCAGTTG	B	6	31.92	6.38		
43	ARDC-120	L	TTCTCCWCAGGAGTC	C	6	19.84	4.02		
44	ARDC-121	L	AGGGCCTCACCACCA	D	6	22.79	4.63		
45	ARDC-122	L	AACACCAAAGATGAT	E	6	30.10	6.03		
46	ARDC-123	L	CCTTACCTGGCAGTG	F	6	29.27	5.90		
47	ARDC-124	L	CAATGGTTCCAGTTG	G	6	25.90	5.18		

# Exhibit B

ch12186601..1AF186601	Homo sapiens haplotype A7 beta-globin...	1744	0.0
ch12186601..1AF186601	Homo sapiens haplotype A11 beta-globin...	1744	0.0
ch12186601..1AF186601	Homo sapiens haplotype A1 beta-globin...	1744	0.0
ch12186601..1AF186601	Homo sapiens haplotype D4 beta-globin...	1737	0.0
ch12186601..1AF186601	Homo sapiens haplotype B19 beta-globin...	1737	0.0
ch12186601..1AF186601	Homo sapiens haplotype B17 beta-globin...	1737	0.0
ch12186601..1AF186601	Homo sapiens haplotype B15 beta-globin...	1737	0.0
ch12186601..1AF186601	Homo sapiens haplotype A11a beta-globin...	1737	0.0
ch12186601..1AF186601	Homo sapiens haplotype D4 beta-globin...	1735	0.0
ch12186601..1AF186601	Homo sapiens haplotype D3 beta-globin...	1729	0.0
ch12186601..1AF186601	Homo sapiens haplotype B22 beta-globin...	1729	0.0
ch12186601..1AF186601	Homo sapiens haplotype C19 beta-globin...	1721	0.0
ch12186601..1AF186601	Homo sapiens beta-globin (HBB) gene...	1566	0.0
ch12186601..1AF186601	Homo sapiens beta-globin (HBB) gene...	1566	0.0
ch12186601..1AF186601	Homo sapiens beta-globin (HBB) gene...	1558	0.0
ch12186601..1AF186601	Homo sapiens beta-globin (HBB) gene...	1558	0.0
ch12186601..1AF186601	Homo sapiens beta-globin (HBB) gene...	1558	0.0
ch12186601..1AF186601	Homo sapiens beta-globin (HBB) gene...	1558	0.0
ch12186601..1AF186601	Homo sapiens beta-globin (HBB) gene...	1552	0.0
ch12186601..1AF186601	Homo sapiens beta-globin (HBB) gene...	1550	0.0
ch12186601..1AF186601	Homo sapiens beta-globin gene, compl...	1461	0.0
ch12186601..1AF186601	Human gene line for beta-globin	1441	0.0
ch12186601..1AF186601	Human thalassemia beta globin gene, co...	1351	0.0
ch12186601..1AF186601	Homo sapiens mutant beta-globin (HBB)	1174	0.0
ch12186601..1AF186601	Monkey (r. polytrama) beta-globin gene...	1136	0.0
ch12186601..1AF186601	Human beta globin Miyada gene on chromo...	1025	0.0
ch12186601..1AF186601	Homo sapiens beta globin (HBB) gene...	820	0.0
ch12186601..1AF186601	Homo sapiens mutant beta-globin (HBB)	228	0.0
ch12186601..1AF186601	Human gene for delta-globin	108	0.0
ch12186601..1AF186601	Crassostrea delta globin gene, complete cds	680	0.0
ch12186601..1AF186601	Spider monkey (A. Geoffroyi) delta-globin...	634	e-179
ch12186601..1AF186601	Human beta-hemoglobin gene, exon 1 a...	521	e-167
ch12186601..1AF186601	Human beta-globin gene alternative trans...	521	e-167
ch12186601..1AF186601	Homo sapiens beta globin (HBB) gene...	572	e-163
ch12186601..1AF186601	Human beta-globin gene mRNA precursor...	572	e-163
ch12186601..1AF186601	T. syrichta beta globin gene, complete cds	572	e-161
ch12186601..1AF186601	Otolentulus crassicaudatus epsilon-, gamma...	484	e-134
ch12186601..1AF186601	C. crassicaudatus beta globin gene, co...	484	e-134
ch12186601..1AF186601	O. crassicaudatus delta globin gene, c...	476	e-132
ch12186601..1AF186601	Homo sapiens hemoglobin beta (HBB), mRNA	446	e-123
ch12186601..1AF186601	Homo sapiens hemoglobin beta subunit...	446	e-123
ch12186601..1AF186601	Homo sapiens hemoglobin beta chain (...)	438	e-120
ch12186601..1AF186601	Human messenger RNA for beta-globin	438	e-120
ch12186601..1AF186601	Human messenger RNA for beta-globin	438	e-120
ch12186601..1AF186601	Human sickle beta-hemoglobin mRNA	438	e-120
ch12186601..1AF186601	Human delta-hemoglobin gene, exon 1 a...	385	e-104
ch12186601..1AF186601	Lemur (brown) beta-globin gene, complete...	378	e-102
ch12186601..1AF186601	Monkey (r. polytrama) delta-globin pseudog...	373	e-101
ch12186601..1AF186601	Monkey (ambis) silent delta-globin gene	365	2e-98
ch12186601..1AF186601	Homo sapiens hemoglobin, delta (HBD), mRNA	361	6e-98
ch12186601..1AF186601	Human sickle cell beta-globin mRNA, c...	359	1e-96
ch12186601..1AF186601	Monkey (rhesus) delta-globin pseudoge...	333	7e-89
ch12186601..1AF186601	Lepus europaeus adult beta-globin gene	281	6e-74
ch12186601..1AF186601	T. syrichta delta-globin gene, complete cds	281	2e-73
ch12186601..1AF186601	Rabbit gene for beta-globin	276	1e-71
ch12186601..1AF186601	Rabbit beta1-globin gene (allele 2)...	276	1e-71
ch12186601..1AF186601	Rabbit beta1-globin with 2 inv, type 2...	276	1e-71
ch12186601..1AF186601	Rabbit beta-like globin gene cluster m...	276	1e-71
ch12186601..1AF186601	Rabbit (O. cuniculus) gene for beta-globin	268	3e-69
ch12186601..1AF186601	Rabbit beta1-globin with 2 inv, type 1...	268	3e-69
ch12186601..1AF186601	Messenger RNA for rabbit beta-globin	256	1e-65
ch12186601..1AF186601	Bovine beta globin gene and globin (PHI-3...	238	1e-60
ch12186601..1AF186601	Bovine adult beta-globin gene	238	2e-60
ch12186601..1AF186601	S. scrofa beta-globin gene	222	2e-55
ch12186601..1AF186601	Sheep beta-C globin gene	222	2e-55
ch12186601..1AF186601	Goat gamma-globin gene, complete cds	222	2e-55
ch12186601..1AF186601	Sheep beta-2 globin gene	214	5e-53
ch12186601..1AF186601	Goat cysteine-beta-globin gene, complet...	202	2e-49
ch12186601..1AF186601	Goat alanine-beta-globin gene, complet...	202	2e-49
ch12186601..1AF186601	Ovis aries fetal globin gene, complete cds	186	1e-44

ch12186601..1AF186601 Human beta globin region on chromosome 11  
Length = 73308

Score = 2260 bits (1140), Expect = 0.0  
Identities = 1240/1140 (100%)  
Strand = Plus / Plus

```

Query: 1      cttaccagaaggttttcaatccaaatcaggagagatctgcttagaacttaggttaggttt 60
Sbjct: 61621 cttaccagaaggttttcaatccaaatcaggagagatctgcttagaacttaggttaggttt 61680

Query: 61     tcattccattctgtctctgttgaatcttctgcatattcttggagacgcaggagagatccatt 120
Sbjct: 61681 tcattccattctgtctctgttgaatcttctgcatattcttggagacgcaggagagatccatt 61740

Query: 121    acatattcccaagctgaattatgtgtagacaaagctcttccactttttagtgcataatttc 180
Sbjct: 61741 acatattcccaagctgaattatgtgtagacaaagctcttccactttttagtgcataatttc 61800

Query: 181    ttattctgtgttaataagaaatttgggaaacagatcttccaatatgcttaccagctgtgatt 240
Sbjct: 61801 ttattctgtgttaataagaaatttgggaaacagatcttccaatatgcttaccagctgtgatt 61860

Query: 241    ccaaatattatcgttaaatccacccgcaaggagagatcttctttagtgcatttttactgat 300
Sbjct: 61861 ccaaatattatcgttaaatccacccgcaaggagagatcttctttagtgcatttttactgat 61920

```

## Exhibit B

Query: 301 ggtatggggcccaagagatatactctttagggggaggggtcagggtttgaagctccactctca 360  
 Subject: 61921 ggtatggggcccaagagatatactctttagggggaggggtcagggtttgaagctccactctca 61980

Query: 361 agccagtgccagagagcagggccaggtacggtctgtaacttagaactccactctg 420  
 Subject: 61981 agccagtgccagagagcagggccaggtacggtctgtaacttagaactccactctg 62040

Query: 421 gagccacacccctagggttggccactctactccaggagcagggtcagggtcagggtc 480  
 Subject: 62041 gagccacacccctagggttggccactctactccaggagcagggtcagggtcagggtc 62100

Query: 481 tgggcataaaagtccagggcagagccatcttctgttactcttcttccgacacactctg 540  
 Subject: 62101 tgggcataaaagtccagggcagagccatcttctgttactcttcttccgacacactctg 62160

Query: 541 ttctactagcaacctccaaacagacacacctctgttactctactctctgagagagctg 600  
 Subject: 62161 ttctactagcaacctccaaacagacacacctctgttactctactctctgagagagctg 62220

Query: 601 ttactgccctgtggggcagggtgaagctgagatgaggttgggtgaggtcaggtcaggt 660  
 Subject: 62221 ttactgccctgtggggcagggtgaagctgagatgaggttgggtgaggtcaggtcaggt 62280

Query: 661 tgggtatcaaggttcaaaagcagggttcaaggagacacatagaaactcgggtcgttggagaca 720  
 Subject: 62281 tgggtatcaaggttcaaaagcagggttcaaggagacacatagaaactcgggtcgttggagaca 62340

Query: 721 gggagagactcttgggtttctgtagggcactgactctctctgacctatgggtctatcttcc 780  
 Subject: 62341 gggagagactcttgggtttctgtagggcactgactctctctgacctatgggtctatcttcc 62400

Query: 781 acccttaggcctgctgggtgcttacccttgggacccagaggttcttttagtctcttggggat 840  
 Subject: 62401 acccttaggcctgctgggtgcttacccttgggacccagaggttcttttagtctcttggggat 62460

Query: 841 ctgtccactcctgtgctgttctatgggcaaccccaaggtgaaggtcctatggcaagagctg 900  
 Subject: 62461 ctgtccactcctgtgctgttctatgggcaaccccaaggtgaaggtcctatggcaagagctg 62520

Query: 901 ctccgtgacctttagtgatgggtcgggtcacttgggtcactcaggggcaaccttggcaca 960  
 Subject: 62521 ctccgtgacctttagtgatgggtcgggtcacttgggtcactcaggggcaaccttggcaca 62580

Query: 961 ctgagtgagctgcaactgggacaggttcaggtgggtcctgagaaactcagggtgagctca 1020  
 Subject: 62581 ctgagtgagctgcaactgggacaggttcaggtgggtcctgagaaactcagggtgagctca 62640

Query: 1021 tggggccctttagtgttt 1080  
 Subject: 62641 tggggccctttagtgttt 62700

Query: 1081 gggagagagtaaacgggttaccgtttagaattgggacacagacgaatgattgcatcaggtctg 1140  
 Subject: 62701 gggagagagtaaacgggttaccgtttagaattgggacacagacgaatgattgcatcaggtctg 62760

Score = 796 bits (356). Expect = 0.0  
 Identities = 491/535 (91%). Gaps = 2/535 (0%)  
 Strand = Plus / Plus

Query: 484 gcatataaggtcagggccagagccatctattgcttactattggttctgacacactctgctc 541  
 Subject: 54707 gcatataaggtcagggccagagccatctattgcttactattggttctgacacactctgctc 54766

Query: 544 actagcaacctcaaacagacacacatggttcacactgactcctgagagagctctgaggtta 603  
 Subject: 54767 actagcaacctcaaacagacacacatggttcacactgactcctgagagagctctgaggtta 54826

Query: 604 ctgccctgttggggcagggtgaagctgaggttgggtgaggtcaggtcaggtcaggtcaggt 663  
 Subject: 54827 ctgccctgttggggcagggtgaagctgaggttgggtgaggtcaggtcaggtcaggtcaggt 54886

Query: 664 taccaggttaccagagagaggttaccagagagagagagagagagagagagagagagagag 723  
 Subject: 54887 taccaggttaccagagagaggttaccagagagagagagagagagagagagagagagagag 54946

Query: 724 aagactcttgggtttctgtagggcactgactctctctgcttactgggtctatctccaccc 783  
 Subject: 54947 aagactcttgggtttctgtagggcactgactctctctgcttactgggtctatctccaccc 55006

Query: 784 ttttgggttcttgggttcttgggttcttgggttcttgggttcttgggttcttgggttcttgg 843  
 Subject: 55005 ttttgggttcttgggttcttgggttcttgggttcttgggttcttgggttcttgggttcttgg 55064

Query: 844 tccacttccgtgctgctcagggcaacctcaaggtcagaggtcctatggcagagagagctc 903  
 Subject: 55065 tccacttccgtgctgctcagggcaacctcaaggtcagaggtcctatggcagagagagctc 55124

*Perfect match!*

**Exhibit B**

arrayit.com/weboligos.com  
confidential

**ARDC-119**

**5' NCA ACT GGG ACC ATT G 3'**

**N = Cy5**

**ARDC-120**

**5' NTT CTC C(T/A)C AGG AGT C 3'**

**N = C6 Amino modifier**

**ARDC-121**

**5' NAG GGC CTC ACC ACC A 3'**

**N = C6 Amino modifier**

**ARDC-122**

**5' NAA CAC CAA AGA TGA T 3'**

**N = C6 Amino modifier**

**ARDC-123**

**5' NCC TTA CCT GGC AGT G 3'**

**N = C6 Amino modifier**

**ARDC-124**

**5' NCA ATG GTT CCA GTT G 3'**

**N = C6 Amino modifier**



**Exhibit B**

arrayit.com/weboligos.com  
confidential

**ARDC-109**

**5' NGG TAG TAA TGA GCG TGC AGC 3'**

**N = C6 Amino modifier**

**ARDC-110**

**5' NGA CTC CTG (A/T)GG AGA A 3'**

**N = Cy3**

**ARDC-111**

**5' NGA CTC CTA (A/T)GG AGA A 3'**

**N = Cy5**

**ARDC-112**

**5' NTG GTG GTG AGG CCC T 3'**

**N = Cy5**

**ARDC-113**

**5' NTG GTG GTA AGG CCC T 3'**

**N = Cy3**

**ARDC-114**

**5' NAT CAT CTT TGG TGT T 3'**

**N = Cy3**

**ARDC-115**

**5' NTA TCA TCG GTG TTT C 3'**

**N = Cy5**

**ARDC-116**

**5' NCA CTG CCA GGT AAG G 3'**

**N = Cy5**

**ARDC-117**

**5' NCA CTG CCG GGT AAG G 3'**

**N = Cy3**

**ARDC-118**

**5' NCA ACT GGA ACC ATT G 3'**

**N = Cy3**

ARDC-100

5' NAA ACA GAC ACC ATG GTG CAC 3'

N = C6 Amino modifier

ARDC-101

5' NCC CAC AGG GCA GTA ACG GCA 3'

N = C6 Amino modifier

ARDC-102

5' NGC AAG GTG AAC GTG GAT GAA 3'

N = C6 Amino modifier

ARDC-103

5' NGT AAC CTT GAT ACC AAC CTG 3'

N = C6 Amino modifier

ARDC-104

5' NCT GGC ACC ATT AAA GAA AAT 3'

N = C6 Amino modifier

ARDC-105

5' NTT CTG TAT CTA TAT TCA TCA 3'

N = C6 Amino modifier

ARDC-106

5' NTG GGC TGT TCT AAC CCC CAC 3'

N = C6 Amino modifier

ARDC-107

5' NAA CCC ACT GGA GCC CCT GAC 3'

N = C6 Amino modifier

ARDC-108


5' NCC ACA GGA TCA GAG GCT GGG 3'

N = C6 Amino modifier



Nucleotide

Homo sapiens galactose-1-phosphate uridylyl transferase (GALT) gene, exon 10, with an N314D mutation prevalent in Duarte galactosemia (M96264 bases 2981-3250)



Go to: 1

Search for:


Comments and suggestions to: [info@ncbi.nlm.nih.gov](mailto:info@ncbi.nlm.nih.gov)

Duarte allele: WT (G, Asn) N → D (mutant)  
mutant (G, Asp) N314D



## Nucleotide

**Human galactase-1-phosphate uridylyl transferase (GALT) gene, exon 6, with a Q188R mutation prevalent in G/Q Caucasian population causing reduced GALT activity (M96264 bases 1681-1870)**



This is the uncut!

18 28 38 48 58 68 78 88  
1 ACACGACGACT TACGTTGCTG TCCTTTTGCTT ACACAGAGCTG CCGTACGACTA TCTATAAGAT  
GALT  
primer\_bind  
70 80 90 100 110 120  
61 CTTTCATGAC ATAGGCTGCG TATGGGCTG TTCTAAGCCG CACCGGACCT CCGCGGTAC  
ARDC=106  
F E N K G A M M C C S N P H P M C R  
Mutation  
138 148 158 168 178 188  
121 GATGATGATG CCGTACGCTG CTTCTTCTGC TACGCTTGAC CACGACGCTT CCGATCTGCG  
ARDC=107  
primer\_bind  
191 ACAC  
GALT  
primer\_bind

$$\begin{aligned} CAG &= \text{Gla}(Q) \\ CGG &= \text{Arg}(R) \end{aligned}$$

Q188R

Go to:  Search for:

Comments and suggestions to: [info@uchicago.edu](mailto:info@uchicago.edu)

WT (a, Glu)  
Mutant (g, Arg)

$$a \rightarrow g$$



5' Nucleotide

Human cystic fibrosis transmembrane conductance regulator (CFTR) gene, exon 10 (331..831)

331	340	350	360	370	380	390
CCACGACCTG	GAGCCTTCAG	ACGCTAATAT	TAGGACACT	CGACGATTG	CATTCTGTC	
CFTR mRNA-C00-120-58						
	G	E	L	E	P	S
	E	G	K	I	K	H
	S	G	R	I	S	F
	C	S				
391	400	410	420	430	440	450
TGCTTTTTC	TGCATTATC	CTGGACCAT	TAAACAAAT	ATCATCTTC	GTCTTCCTA	
CFTR mRNA-C00-120-58						
	Q	F	S	H	I	P
	C	T	I	K	E	N
	I	I	P	C	V	S
	Y					
451	460	470	480	490	500	510
TCATGATAT	AGTAGACAA	GGGTATCAN	AGCATCCCA	CTAGACACC	TAGCAACTA	
CFTR mRNA-C00-120-58						
	D	E	Y	R	V	I
	K	A	C	Q	L	E
511	520	530	540	550	560	570
TCTGAACT	TTTGATTAT	CGATGAC	CTTGACACT	ACCGATTAT	TATATTGCG	
CFTR mRNA-C00-120-58						
571	580	590	600	610	620	630
TCCATATTC	ATCGTTACT	CTCATATAT	TTATCTTTC	TCTATGGTA	ACCTACTGTG	
CFTR mRNA-C00-120-58						
631	640	650	660	670	680	690
ATGCAATCA	TTATTAATC	ACATGACCA	TGCTTTTACA	ACCTTGCAA	CAGATCAAT	
CFTR mRNA-C00-120-58						
691	700	710	720	730	740	750
AAATGCAAT	TATTTTATA	ATAATGCTT	CTTTGATCA	CAATATATC	ATTATATCA	
CFTR mRNA-C00-120-58						
751	760	770	780	790	800	810
ATGCTGACA	TTTGTTCAC	TGATTTCTA	CAATACCTC	TGATCTTCA	TTTATATCC	
CFTR mRNA-C00-120-58						
811	820	830				
ATCATATAC	TGATATGCG	T				
CFTR mRNA-C00-120-584						

$\Delta F508$   
 $\Delta TTT = \Delta Phe$   
 $TTT = Phe(F)$

(1...831)

331

$\Delta F508 = 3 \text{ nt. deletion of WT sequence}$

Comments and suggestions to: [info@ncbi.nlm.nih.gov](mailto:info@ncbi.nlm.nih.gov)



Nucleotide

Human beta-globin gene from a thalassemia patient, complete cds (921..1852)

920 940 960 980 970 980  
 921 CTATTTTTC ACATATTTA TTACATTCR TGACCAATT ACACAAACA ACACAAATC  
 940 1000 1010 1020 1030 1040  
 961 ATCCATATA TATGTATATC TATCTCTGA CATATACCA TATATATAT TATTTTTTT  
 1050 1060 1070 1080 1090 1100  
 1041 CTTTCTTTC CAGACCTTT TATCCAAAT AACAGACCA TATCTTACA ACTACCTAC  
 1110 1120 1130 1140 1150 1160  
 1101 ACTTTCATC CATCTGTCC TCTATGATT TTCCATATC TCCACACCA GACAGACATC  
 1170 1180 1190 1200 1210 1220  
 1161 CATCTACATA TCCCAAGCT GATTATGCT ACACAAACT CTTCACCTT TAGTCATCA

1230 1240 1250 1260 1270 1280  
 1221 ATTCTTATT TGTGTAATA CAAATTTGG AATACCATCT TCAATATCT TACCAACTG  
 1290 1300 1310 1320 1330 1340  
 1281 TCAITCCAA TATTACCTA ATACCTTCC AATCCACTT GTTTTACTA CCAATTTCTA  
 1350 1360 1370 1380 1390 1400  
 1341 CTCTCTGAT GCGCCACCA CATATATCT ACACCAACG CTGACGCTT CAGTCCAC  
 1410 1420 1430 1440 1450 1460  
 1401 TCTTAGGCA CTCCACACG ACCACACAC AGTACGCTT GTGATCTCT AGACCTCAC  
 1470 1480 1490 1500 1510 1520  
 1461 CTCTCGGCC ACACCTACG CTCTCCCAT CTACTCGAC GACACGACG CCGACGACG

1530 1540 1550 1560 1570 1580  
 1521 AGCCCTGCC ATAAATCTA CCGACACCC ATCTATTCT TACTTTGCT TCTGACACA  
 1590 1600 1610 1620 1630 1640  
 1581 CTCTCTTAC TACCACTTC AACACACG CATCTCTCC CTACTCTCT ACACGACG

1650 1660 1670 1680 1690 1700  
 1641 TCCCTTACT CCGCTCTCG CACAGCTCA CAGTATGCA GTTCTGCTG CCGCTCTCG  
 1710 1720 1730 1740 1750 1760  
 1701 CAGTCTCTA TCAACCTTC AACACGCTT TACAGACG CACACAACT CCGCTCTCG

1770 1780 1790 1800 1810 1820  
 1761 AACACAACT CAGTCTCTG TTCTGTATG CAGCTCTCT TCTCTGCTA TTCTCTATT

1830 1840 1850  
 1821 TTCCACGCT TACCTCTCT GTCTCTAC CT

1830 1840 1850  
 1821 TTCCACGCT TACCTCTCT GTCTCTAC CT

G172A = C allele  
 A173T = S allele  
 G232A = E allele

GAG(Glu) → AAG(Lys)  
 GAG(Glu) → GTG(Val)  
 GAG(Glu) → AAG(Lys)

Exon 1

ARDC-101

ARDC-100

ARDC-102

ARDC-103

Use 6/3/98 formula  
 from Schena with.

$$T_c = -682 \times (f^{-1}) + 97 \quad [921]$$

$$T_m = T_c - 10^\circ\text{C}$$

$$15\text{-mer } -T_m = 42^\circ\text{C}$$

$$13\text{-mer } -T_m = 35^\circ\text{C}$$

$$11\text{-mer } -T_m = 25^\circ\text{C}$$

$$9\text{-mer } -T_m = 11^\circ\text{C}$$

$$10\text{-mer } T_m = 19^\circ\text{C}$$

## Exhibit B

### Neonatal Screening

Obtain 108 samples from Neo Gen

6 rows of 12 PCR tubes

Correspond to CF, B-globin and other loci and to Neo Gen samples A, B, C, D, E and F

50 ul PCR with 15 ul missing for agarose gels (gel bands look good)

Products look OK

All stored at -80C since arrival on

Remove from -80C, 72 samples and thaw

These correspond to 6 human loci, with quads of each locus and each genotype (wt, hetero and homo)

-Such that a given locus has 12 tubes

A. deltaF508WT, Hetero, Homo

B. B-globin 172/173 S/S, A/S, S/C

C. B-globin 172/173 C/C, A/C, A/A

D. B-globin 232 E/E, A/E, A/A

E. GALT 314 WT, Hetero, Homo

F. GALT 188 WT, Hetero, Homo

Add 160 ml of binding buffer

Mix 10X

Add to 384-well filter plate

-Add so that each set of four occupies a quad of wells

-ie. The first set of four is in A1, A2, B1, B2 and so forth

-Leave the 10<sup>th</sup> set of wells (A9, A10, B9, B10) empty so that samples will fall on even rows when printing 30 x30 in triplicate. ie. Last set of three spots will be empty for the first row.

Add 3 times to filter entire 200 ul vol

Spin briefly between loadings, then 5 min to dry filter

Add 50 ul H<sub>2</sub>O, wait 2 min and elute by cent for 5 min

Allow 384-well plate to dry o/n under hood fan to dryness

After o/n drying under hood, the samples still contained ~20ul liquid

Dry in speedvac for 1.5 hrs at medium heat.

Add 5 ul H<sub>2</sub>O to each well and mix well

Add 5 ul of 2X MSS-1 to each well and mix

To new 384-well plate, transfer 3 ul of each sample.

Also, add 3 ul to 5 additional quads of wells for each of 5 control 15-mer oligos

-Oligos are A5, B5, C5, D5, E5 (ARDC120-124) from weboligos 3/21/00 plate stored at -20C

-Oligos are amino-mods at 100 uM concentration, diluted 1:1 with 2X MSS-1 for a final conc of 50 uM.

Spin plate 5 min at 500 x g to move samples to bottom of plate

Array onto 30 SuperAldehydes using triplicate spotting at 140 uM spacing and 30 x 30 config

-Note that final arrays should contain 4 identical subgrids with 2 complete rows and the third containing 12 spots. The final 3 spots in row 1 should be 1X MSS-1

Printing looks good!

Store arrays in a substrate box for processing.

After o/n drying, label 2 arrays barcoded # 105034 and 105035

Demarcate array with diamond pencil on underside

Process as per published protocols

Soak 2X in 0.2% SDS

Soak 2X in dH<sub>2</sub>O

Treat for 2 min at 95C in dH<sub>2</sub>O

Spin dry 1 min

## Exhibit B

Treat for 5 min in sodium borohydride (1.0 g in 400 ml dH<sub>2</sub>O)  
Rinse 3X in 0.2% SDS  
Rinse 1X in dH<sub>2</sub>O  
Treat 2 sec at 95C in dH<sub>2</sub>O  
Spin dry 1 min

### Hybridization:

Set array in hyb cassette  
Add 10 ul of dH<sub>2</sub>O  
Prepare 2 cover slips 22 mm x 22 mm  
Lay cover slip on top of array  
Add 10 ul of 2-color fluorescent probes

- Probe are mixtures of 10 fluorescent oligos (5 Cy3 and 5 Cy5)
- Oligos are from weboligos 3/21/00 plate
- Cy3 are A1, B1, C1, D1 and E1
- Cy5 are A3, B3, C3, D3 and E3
- All 10 are in a 10 uM mixture stored at -20C

Probe 1: 10 oligos at 1 uM each final conc in 1X UniHyb  
Probe 2: 10 oligos at 1 uM each final conc in 5X SSC + 0.2% SDS  
Add probe 1 to array 105034 and probe 2 to array 105035  
Hyb at 42C for 1.5 hrs  
Wash 2X in 2X SSC + 0.2% SDS and 1X in 2X SSC for 5 min each  
Spin dry 1 min  
Scan at 100% PMT and 100% laser

### Results:

Signals are rather weak but background is very low  
Looks like the experiment is working!  
See scans ms000420a-d  
a-Cy3 with array 105034  
b-Cy5 with array 105034  
c-Cy3 with array 105035  
d-Cy5 with array 105035

Second chip (SSC and SDS) slightly brighter signal. Quant data

### Processing:

Process chips and compare direct labeling vs. NEN TSA on neonatal chips  
Obtain 4 chips from rt drawer. Chips were made on SuperAldehyde on 4/19/00  
Bar code as 105227-105230  
Mark array with diamond pencil  
Wash 2 x 2 min in 0.2% SDS and 2 x 2 min in dH<sub>2</sub>O.  
Denature 2 min at 95-100C in dH<sub>2</sub>O.  
Reduce in NaBH<sub>4</sub> for 5 min at rt [320 ml dH<sub>2</sub>O + 1.2 g NaBH<sub>4</sub> + 120 ml 100% ethanol]  
Wash 2 x 2 min in 0.2% SDS, 2 x 2 min in dH<sub>2</sub>O. Spin dry.  
Use for Hyb.

Hybs:



## Exhibit B

### Probes-

1. The Cy3/Cy5 mixture prepared on 4/20/00 and stored frozen at -20C. Mixture of 5 Cy3 oligos and 5 Cy5 oligos end-labeled corresponding to 1A-E and 3A-F from 3/24/00 weboligos source. All at 10 uM each. Make hyb mixture by mixing:

- 3 ul of 10 uM oligo mix
- 7.5 ul of 20X SSC
- 6 ul of 1% SDS
- 13.5 ul of dH2O
- 30 ul total volume.

Heat for 1 min at 65C

Spin for 1 min

Hyb to 105227 and 105228 under 22 mm x 22 mm cover slip, using 10 ul hyb solution per chip.

2. The biotin/DNA mixture prepared fresh on 6/7/00 and stored frozen at -20C after use. Mixture of 5 biotin oligos and 5 DNP oligos end-labeled corresponding to 1A-E and 7A-B from 5/24/00 weboligos source. All at 10 uM each. Make hyb mixture by mixing:

- 3 ul of 10 uM oligo mix
- 7.5 ul of 20X SSC
- 6 ul of 1% SDS
- 13.5 ul of dH2O
- 30 ul total volume.

Heat for 1 min at 65C

Spin for 1 min

Hyb to 105229 and 105230 under 22 mm x 22 mm cover slip, using 10 ul hyb solution per chip and 10 ul dH2O for humidification.

Hyb 4.5 hrs at 42C

Wash 2 x 5 min in 2X SSC + 0.2% SDS and 1 x 5 min in 2X SSC

Spin dry.

Scan chips 105227 and 105228 at 100% PMT and 100% laser with ScanArray 3000.

# Exhibit B

		Cy3 raw	Cy3 Ave.	Cy3 Ave-Backgr.	Cy5 raw	Cy5 Ave.
Spot 28	1X MSS-1	2779			949	
Spot 29	"	3063	2964	0	1106	1123
Spot 30	"	3021			1313	
Spot 31	B-globin 232E/E	4986			1396	
Spot 32	B-globin 232E/E	5246	5358	2404	1395	1606
Spot 33	B-globin 232E/E	5841			2028	
Spot 34	B-globin 232A/E	3918			1831	
Spot 35	B-globin 232A/E	3706	3831	877	1429	1566
Spot 36	B-globin 232A/E	3868			1439	
Spot 37	B-globin 232A/A	3483			2871	
Spot 38	B-globin 232A/A	3126	3319	365	3133	2715
Spot 39	B-globin 232A/A	3347			2141	
		46384			21031	

Quantitation of two color genotyping on Neonatal chips printed on 4/19/00

Mixture of 10 fluorescent oligos to 5 loci in Cy3 and Cy5

Hyb buffer was 5X SSC + 0.2% SDS for 1.5 hrs at 42C

Probe solution was 1 uM each oligo

Washes were RT in 2X SSC + 0.2% SDS twice and once in 2X SSC

Scans were on GSIL 3000 at 100% laser and 100% PMT

## Exhibit B





Exhibit B



## Exhibit B



Exhibit B




Exhibit B




Exhibit B







Exhibit B



## Exhibit B

